Core Insights - The Hong Kong innovative drug sector is gaining market attention despite an overall market downturn, driven by several key developments [1][3][4] Group 1: Market Developments - The release of the first version of the "Commercial Health Insurance Innovative Drug Directory" on December 7, 2025, opens a "second payment channel" for high-value innovative drugs, injecting new momentum into the innovative drug industry [1][3] - The launch of the Chinese drug price registration system on December 2, 2025, aims to establish a global pricing system, potentially benefiting Chinese innovative drugs in international markets and attracting high-quality foreign drugs [1][3] - An announcement on December 9, 2025, from an innovative drug company regarding a $150 million upfront payment and up to $350 million in milestone payments for a business development deal indicates ongoing progress in the internationalization of Chinese innovative drugs [1][3] Group 2: Fund Performance - The Hang Seng Innovative Drug ETF (520500) has seen a significant inflow of funds, accumulating 154 million yuan over two trading days (December 8-9, 2025), with a record net inflow of 123 million yuan on December 9, 2025 [2][4] - Trading volume for the ETF has increased, with recorded transaction amounts of 680 million yuan and 780 million yuan over the last two days, compared to an average daily trading volume of 453 million yuan in the first five days of December [2][4] - As of December 9, 2025, the ETF's shares reached 1.203 billion, marking a historical high since its inception on December 16, 2024, with a total asset size of 2.031 billion yuan [2][4] Group 3: Index Composition - The Hang Seng Innovative Drug Index, which the ETF closely tracks, includes companies involved in the research, development, and production of innovative drugs, emphasizing firms with strong R&D capabilities [2][4] - The top five constituents of the index as of December 9, 2025, are Kangfang Biotech, China National Pharmaceutical Group, BeiGene, Innovent Biologics, and Kelun-Biotech [2][4] Group 4: Investment Outlook - The innovative drug sector in Hong Kong has experienced a notable correction since September 2025, but favorable policy and industry developments, along with expectations of U.S. Federal Reserve interest rate cuts and liquidity easing, suggest a potential investment window [2][4] - The Hang Seng Innovative Drug ETF (520500) is characterized by its large scale, favorable liquidity, and support for T+0 trading, making it an efficient tool for investors looking to capitalize on opportunities in the Hong Kong innovative drug sector [2][4]

Group 1 - The core viewpoint of the report is that the National Medical Insurance Administration (NMI) is encouraging the high-quality development of innovative drugs, with a clear trend towards supportive payment policies for innovative drugs, indicating that leading domestic innovative drug companies are entering a commercial realization phase [1] - The 2025 National Medical Insurance Drug List includes 127 products participating in bidding, with 114 drugs successfully added, of which 50 are Class 1 innovative drugs, accounting for 44%, marking a historical high [1] - The overall negotiation success rate is 90%, the highest in nearly seven years, while the success rate for drug applications is 18%, up by 2.5 percentage points year-on-year [1] Group 2 - The Chinese innovative drug market is experiencing accelerated differentiation, with a few leading domestic innovative drug companies contributing significantly to the newly included innovative drugs, indicating a concentration effect [2] - Heng Rui is the biggest winner with 20 innovative drugs/indications included, including 10 new entries, while Innovent Biologics follows with 7 innovative drugs, 6 of which are newly included [2] - The first version of the commercial insurance directory has three key highlights: only 19 out of 121 new drugs passed the formal review, 5 domestic CAR-T therapies were included, and 14 out of 19 drugs are oncology-related, accounting for 74% [4]

Investment Rating - The report rates the pharmaceutical and biotechnology industry as "Outperforming the Market" [1][8]. Core Insights - The report highlights a significant increase in the success rate of negotiations for high-value innovative drugs, with the 2025 National Medical Insurance Directory adding 114 new drugs, including 50 innovative drugs, and achieving a negotiation success rate of 88%, up from 76% in 2024 [3]. - The introduction of a commercial insurance drug directory marks a new phase in healthcare, aiming to create a multi-layered insurance system that complements basic medical insurance, with 19 innovative drugs included in the first version [3]. - The report emphasizes the potential for Chinese innovative drugs to expand internationally, with a focus on ADCs, bispecific antibodies, small nucleic acids, and weight-loss drugs as key investment opportunities [3]. Summary by Sections Industry Performance - The SW Pharmaceutical and Biotechnology Index decreased by 0.74% in the week of December 1-7, underperforming the Shanghai and Shenzhen 300 Index, which increased by 1.28% [2]. - Within the pharmaceutical sector, the drug distribution (+6.48%) and offline pharmacy (+1.85%) segments performed relatively well, while raw materials (-2.54%), vaccines (-1.62%), and CXO (-1.29%) segments showed weaker performance [2]. National Medical Insurance Directory - The 2025 version of the National Medical Insurance Directory will officially implement on January 1, 2026, with a total of 3,253 drugs included, enhancing coverage for critical areas such as oncology, chronic diseases, mental health, rare diseases, and pediatric medications [3]. - Notably, 105 of the newly added drugs are exclusive products, including 98 Western medicines and 7 traditional Chinese medicines [3]. Commercial Insurance Drug Directory - The first version of the commercial insurance innovative drug directory includes 19 drugs, focusing on high clinical value and significant patient benefits, which are beyond the scope of basic medical insurance [5]. - This directory includes treatments for rare diseases, cancer therapies, and Alzheimer's disease, establishing a foundation for the development of a multi-tiered medical insurance system [3][5]. Investment Recommendations - The report suggests a positive outlook for the international expansion of Chinese innovative drugs and recommends monitoring ADCs, bispecific antibodies, small nucleic acids, and weight-loss drugs for investment opportunities [3]. - Key companies to watch include Yiming Biotechnology-B, WuXi AppTec, Maiwei Biotechnology-U, Kelun-Biotech, and Kangfang Biotech [3].

Core Viewpoint - The Hong Kong stock market's innovative pharmaceutical sector is experiencing a buying surge as investors seek to capitalize on recent price adjustments, with significant net inflows into the Hong Kong Stock Connect Innovative Drug ETF (520880) [1][9]. Group 1: Market Activity - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw over 56 million yuan in net subscriptions over two consecutive days, marking a near one-month high in daily inflow, totaling over 113 million yuan [1][9]. - The index for the ETF has experienced a decline of over 18% since early September, indicating a substantial adjustment period that has released prior high-level risks [3][11]. Group 2: Industry Outlook - Continuous policy support for the pharmaceutical industry's innovation is evident, with the recent release of the 2025 National Medical Insurance Drug List, which added 114 new drugs, including 50 innovative drugs, achieving a historical success rate of 88% [5][13]. - The dual implementation of the medical insurance and commercial insurance drug lists is expected to provide a more stable policy outlook for innovative drugs, benefiting related companies [5][13]. Group 3: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) is characterized by three unique advantages: it exclusively covers innovative drug companies, has a significant concentration of leading firms with over 72% weight in the top ten stocks, and employs measures to control risks associated with less liquid stocks [5][6][13]. - As of November 30, the ETF had a scale of 2.142 billion yuan and an average daily trading volume of 458 million yuan, making it the largest and most liquid ETF tracking the same index [7][14].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry, indicating an expected return that is stronger than the market benchmark by over 5% [5]. Core Insights - The National Medical Insurance Administration is strongly encouraging the high-quality development of innovative drugs, with clear policies supporting the payment side for innovative drugs. Domestic leading innovative drug companies are entering a commercial realization phase [3][7]. - The 2025 National Medical Insurance Drug List includes 127 products, with 114 successfully added, of which 50 are innovative drugs, marking a historical high. The overall negotiation success rate reached 90%, the highest in nearly seven years [7]. - The report highlights that the domestic innovative drug market is becoming increasingly concentrated, with leading companies like Heng Rui and Xin Da Biotech significantly benefiting from the new insurance policies [7]. Summary by Sections Investment Recommendations and Targets - Recommended stocks include Heng Rui Pharmaceutical (600276, Buy), Ke Lun Pharmaceutical (002422, Buy), Xin Li Tai (002294, Hold), Ao Sai Kang (002755, Buy), Jing Xin Pharmaceutical (002020, Buy), and others [3]. Market Dynamics - The report notes that the introduction of the commercial insurance directory marks the beginning of a "new golden decade" for Chinese innovative drugs, with a focus on high clinical efficacy and value innovation [7]. - The report emphasizes that the competition in the GLP-1 market remains clear, with the entry of new drugs not significantly altering the competitive landscape for existing treatments [7].

从连续性进行统计， 有1只股获南向资金连续3天以上净买入，连续净买入天数较多的有小米集团-W， 连续净买入天数分别为8天。以其间净买入金额统计，净买入金额最多的是小米集团-W，合计净买入为 67.79亿港元。（数据宝） | 代码 | 简称 | 成交金额 | 成交净买入 | 今日涨跌幅（%） | | --- | --- | --- | --- | --- | | | | （万港元） | （万港元） | | | 00700 | 腾讯控股 | 491742.93 | 87764.01 | -0.41 | | 01810 | 小米集团-W | 452398.77 | 53999.37 | -3.10 | | 09988 | 阿里巴巴-W | 735167.81 | 42544.69 | -1.63 | | 01288 | 农业银行 | 111432.77 | 30679.90 | 0.88 | | 01347 | 华虹半导体 | 161787.89 | 25044.14 | -5.41 | | 01801 | 信达生物 | 50561.70 | 17926.38 | -1.40 | | 06869 | 长飞光纤光缆 ...

Market Overview - On December 9, the Hang Seng Index fell by 1.29%, closing at 25,434.23 points, with a net inflow of HKD 531 million through the southbound trading channel [1][2] - The total trading volume for the southbound trading on December 9 was HKD 96.695 billion, with a net buying of HKD 531 million [1] Southbound Trading Details - In the Shanghai Stock Exchange southbound trading, the total trading amount was HKD 60.3 billion, with a net selling of HKD 35.2 million; in the Shenzhen Stock Exchange, the total trading amount was HKD 36.396 billion, with a net buying of HKD 88.3 million [1] - The top active stocks in the southbound trading included Alibaba-W, Xiaomi Group-W, and Tencent Holdings, with trading amounts of HKD 41.15 billion, HKD 33.21 billion, and HKD 29.30 billion respectively [1][2] Stock Performance - In terms of net buying, Tencent Holdings led with a net buying amount of HKD 112.56 million, despite a closing price drop of 0.41% [1][2] - The stock with the highest net selling was Pop Mart, with a net selling amount of HKD 43.83 million, closing down by 5.04% [1][2] - In the Shenzhen Stock Exchange, Alibaba-W had a trading amount of HKD 32.37 billion, followed by Tencent Holdings and SMIC with amounts of HKD 19.87 billion and HKD 15.03 billion respectively [2] Summary of Active Stocks - The top ten active stocks in the southbound trading included: - Alibaba-W: Trading amount of HKD 411.5 million, net buying of HKD 83.45 million, down by 1.63% - Xiaomi Group-W: Trading amount of HKD 332.1 million, net buying of HKD 156.18 million, down by 3.10% - Tencent Holdings: Trading amount of HKD 293.0 million, net buying of HKD 112.56 million, down by 0.41% - Pop Mart: Trading amount of HKD 188.0 million, net selling of HKD 43.83 million, down by 5.04% [2]

Core Viewpoint - The Hong Kong stock market for innovative drugs continues to decline, with the Hang Seng Index falling below the six-month moving average, indicating ongoing adjustments in the sector [1][3]. Market Performance - On December 9, the Hong Kong innovative drug ETF (520880) experienced a decline of 1.99%, marking two consecutive days of losses, with a trading volume of 283 million yuan [1]. - Major stocks within the ETF saw significant declines, including Kangfang Biotech down 4%, Sanofi Biotech down 3.63%, and Innovent Biologics down 1.4% [1]. Investment Opportunities - Analysts suggest that the current market conditions may present a favorable opportunity for long-term investment in core innovative drug assets, as the index has retraced over 18% since early September, indicating a sufficient adjustment and risk release [3]. - There are positive signals in the funding landscape, with over 56 million yuan net subscriptions for the innovative drug ETF on the previous day, the highest in nearly a month, indicating strong buying interest [4]. Policy Developments - The 2025 National Medical Insurance Drug List has successfully added 114 new drugs, including 50 innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [5]. Business Development - Kelun-Biotech has granted exclusive rights to Crescent for the development of ADC drug SKB105 outside Greater China, along with exclusive rights for CR-001 bispecific antibody in Greater China, which includes an upfront payment of 80 million USD and potential milestone payments of up to 1.25 billion USD [6]. - Analysts recommend focusing on innovative drug companies with rich pipeline layouts, high potential single products, and leading technology platforms [6]. ETF Characteristics - The Hong Kong innovative drug ETF (520880) has a significant concentration in leading companies, with the top ten holdings accounting for over 72% of the index, showcasing the strength of the innovative drug sector [7]. - The ETF has a total market value of 2.142 billion yuan and has the highest liquidity among similar ETFs, with an average daily trading volume of 458 million yuan since its inception [7].

Core Insights - On December 9, 2025, Alibaba-W (09988), Xiaomi Group-W (01810), and Tencent Holdings (00700) were the top three companies by trading volume in the southbound trading of the Stock Connect, with trading amounts of 4.115 billion, 3.321 billion, and 2.930 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Tencent Holdings (00700), and SMIC (00981) led the trading volume, with amounts of 3.237 billion, 1.987 billion, and 1.503 billion respectively [1] Southbound Trading Highlights - **Top Active Companies in Southbound Trading (Shanghai-Hong Kong Stock Connect)** - Alibaba-W (09988): Trading amount of 4.115 billion, net inflow of 83.45 million [2] - Xiaomi Group-W (01810): Trading amount of 3.321 billion, net inflow of 156 million [2] - Tencent Holdings (00700): Trading amount of 2.930 billion, net inflow of 1.126 billion [2] - SMIC (00981): Trading amount of 2.806 billion, net outflow of 133 million [2] - Pop Mart (09992): Trading amount of 1.880 billion, net outflow of 438 million [2] - **Top Active Companies in Southbound Trading (Shenzhen-Hong Kong Stock Connect)** - Alibaba-W (09988): Trading amount of 3.237 billion, net inflow of 342 million [2] - Tencent Holdings (00700): Trading amount of 1.987 billion, net outflow of 248 million [2] - SMIC (00981): Trading amount of 1.503 billion, net inflow of 14.69 million [2] - Xiaomi Group-W (01810): Trading amount of 1.203 billion, net inflow of 384 million [2] - Pop Mart (09992): Trading amount of 1.016 billion, net outflow of 136 million [2]

| 代码 | 简称 | 收盘价 | 不正发明 | 净买入金额 | | | --- | --- | --- | --- | --- | --- | | | | (港元) | (%) | (亿港元) | | | 0700.HK | 腾讯控股 | 602.5 | -0.41 | 8.78 | . | | 1810.HK | 小米集团-W | 41.26 | -3.10 | 5.40 | . | | 9988.HK | 阿里巴巴-W | 150.9 | -1.63 | 4.25 | . | | 1288.HK | 农业银行 | 5.71 | 0.88 | 3.07 | | | 1347.HK | 华虹半导体 | 75.15 | -5.41 | 2.50 | | | 1801.HK | 信达生物 | 84.4 | -1.40 | 1.79 | | | 6869.HK | 长飞光纤光缆 | 37.92 | 4.35 | 0.58 | . | | 9926.HK | 康方生物 | 119.4 | -4.02 | 0.43 | . | | 0883.HK | 中国海洋石油 | 21.06 | -2.41 | -0.44 | ...